Statins are associated with reduced risk of esophageal cancer, particularly in patients with barrett's esophagus: A systematic review and meta-analysis

Clinical Gastroenterology and Hepatology

Volumn 11, Issue 6, 2013, Pages 620-629

  Singh, Siddharth ^a   Singh, Abha Goyal ^a   Singh, Preet Paul ^a   Murad, Mohammad Hassan ^a   Iyer, Prasad G ^a  

^a MAYO CLINIC   (United States)

Author keywords

Chemoprevention; Cholesterol Lowering Drugs; Esophageal Cancer Risk; HMG CoA Reductase Inhibitors

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT;

ANTINEOPLASTIC ACTIVITY; BARRETT ESOPHAGUS; CANCER PATIENT; CANCER RISK; DRUG EFFECT; ESOPHAGUS CANCER; HUMAN; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; RISK REDUCTION; SYSTEMATIC REVIEW; COMPLICATION; ESOPHAGEAL NEOPLASMS; INCIDENCE; RISK ASSESSMENT;

ANTICHOLESTEREMIC AGENTS; BARRETT ESOPHAGUS; ESOPHAGEAL NEOPLASMS; HUMANS; INCIDENCE; RISK ASSESSMENT;

EID: 84878135553     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2012.12.036     Document Type: Review

References (54)

1. Jemal A., Bray F., Center M.M., et al. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Bosetti C., Levi F., Ferlay J., et al. Trends in oesophageal cancer incidence and mortality in Europe. Int J Cancer 2008, 122:1118-1129.
3. Cook M.B., Chow W.H., Devesa S.S. Oesophageal cancer incidence in the United States by race, sex, and histologic type, 1977-2005. Br J Cancer 2009, 101:855-859.
4. Sharma P. Clinical practice. Barrett's esophagus. N Engl J Med 2009, 361:2548-2556.
5. Corley D.A., Levin T.R., Habel L.A., et al. Surveillance and survival in Barrett's adenocarcinomas: a population-based study. Gastroenterology 2002, 122:633-640.
6. Inadomi J.M., Sampliner R., Lagergren J., et al. Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis. Ann Intern Med 2003, 138:176-186.
7. Bonovas S., Filioussi K., Tsavaris N., et al. Statins and cancer risk: a literature-based meta-analysis and meta-regression analysis of 35 randomized controlled trials. J Clin Oncol 2006, 24:4808-4817.
8. Kuoppala J., Lamminpää A., Pukkala E. Statins and cancer: a systematic review and meta-analysis. Eur J Cancer 2008, 44:2122-2132.
9. Singh S., Singh P.P., Singh A.G., et al. Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology 2013, 144:323-332.
10. Demierre M.F., Higgins P.D., Gruber S.B., et al. Statins and cancer prevention. Nat Rev Cancer 2005, 5:930-942.
11. Ogunwobi O.O., Beales I.L. Statins inhibit proliferation and induce apoptosis in Barrett's esophageal adenocarcinoma cells. Am J Gastroenterol 2008, 103:825-837.
12. Konturek P.C., Burnat G., Hahn E.G. Inhibition of Barret's adenocarcinoma cell growth by simvastatin: involvement of COX-2 and apoptosis-related proteins. J Physiol Pharmacol 2007, 58(Suppl 3):141-148.
13. Sadaria M.R., Reppert A.E., Yu J.A., et al. Statin therapy attenuates growth and malignant potential of human esophageal adenocarcinoma cells. J Thorac Cardiovasc Surg 2011, 142:1152-1160.
14. Ye F., Zhang G.H., Guan B.X., et al. Suppression of esophageal cancer cell growth using curcumin, (-)-epigallocatechin-3-gallate and lovastatin. World J Gastroenterol 2012, 18:126-135.
15. Nguyen D.M., Richardson P., El-Serag H.B. Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus. Gastroenterology 2010, 138:2260-2266.
16. Kastelein F., Spaander M.C., Biermann K., et al. Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus. Gastroenterology 2011, 141:2000-2008. quiz e13-e14.
17. Beales I.L., Vardi I., Dearman L. Regular statin and aspirin use in patients with Barrett's oesophagus is associated with a reduced incidence of oesophageal adenocarcinoma. Eur J Gastroenterol Hepatol 2012, 24:917-923.
18. Kantor E.D., Onstad L., Blount P.L., et al. Use of statin medications and risk of esophageal adenocarcinoma in persons with Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 2012, 21:456-461.
19. Vinogradova Y., Coupland C., Hippisley-Cox J. Exposure to statins and risk of common cancers: a series of nested case-control studies. BMC Cancer 2011, 11:409.
20. Higgins JPT, Green S (eds). Cochrane handbook for systematic reviews of interventions, version 5.1.0 (updated March 2011). The Cochrane Collaboration 2012. Available at: Accessed August 15, 2012. http://www.cochrane-handbook.org.
21. Kanwal F., White D. "Systematic Reviews and Meta-analyses" in clinical gastroenterology and hepatology. Clin Gastroenterol Hepatol 2012, 10:1184-1186.
22. Stroup D.F., Berlin J.A., Morton S.C., et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA 2000, 283:2008-2012.
23. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available at: Accessed September 30, 2012. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
24. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
25. Higgins J.P., Thompson S.G., Deeks J.J., et al. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
26. Thompson S.G., Pocock S.J. Can meta-analyses be trusted?. Lancet 1991, 338:1127-1130.
27. Guyatt G.H., Oxman A.D., Kunz R., et al. GRADE guidelines: 7. Rating the quality of evidence-inconsistency. J Clin Epidemiol 2011, 64:1294-1302.
28. Begg C.B., Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 50:1088-1101.
29. Easterbrook P.J., Berlin J.A., Gopalan R., et al. Publication bias in clinical research. Lancet 1991, 337:867-872.
30. Ferlay J., Shin H.R., Bray F., et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917.
31. Sikkema M., de Jonge P.J., Steyerberg E.W., et al. Risk of esophageal adenocarcinoma and mortality in patients with Barrett's esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2010, 8:235-244. quiz e32.
32. Wani S., Puli S.R., Shaheen N.J., et al. Esophageal adenocarcinoma in Barrett's esophagus after endoscopic ablative therapy: a meta-analysis and systematic review. Am J Gastroenterol 2009, 104:502-513.
33. Desai T.K., Krishnan K., Samala N., et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysis. Gut 2012, 61:970-976.
34. Bhutta H.Y., Clark A., Holt S., et al. Cancer - an aetiological investigation into the potential protective effect of statins in the UK General Practice Research Database (GPRD). Gastroenterology 2011, 140:S166.
35. Friedman G.D., Flick E.D., Udaltsova N., et al. Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf 2008, 17:27-36.
36. Kaye J.A., Jick H. Statin use and cancer risk in the general practice research database. Br J Cancer 2004, 90:635-637.
37. Khurana V., Chalasani R., Caldito G., et al. Statins reduce the incidence of esophageal cancer: a study of half a million US veterans. Gastroenterology 2005, 128:A93.
38. Marelli C., Gunnarsson C., Ross S., et al. Statins and risk of cancer: a retrospective cohort analysis of 45,857 matched pairs from an electronic medical records database of 11 million adult Americans. J Am Coll Cardiol 2011, 58:530-537.
39. Altawil J., Irwin B., Jinjuvadia R., et al. Statins might not prevent progression to dysplasia and cancer in Barrett's esophagus. Am J Gastroenterol 2011, 106:S32.
40. Emberson J.R., Kearney P.M., et al. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS ONE 2012, 7:e29849. Cholesterol Treatment Trialists' CTT Collaboration.
41. Lai S.W., Liao K.F., Lai H.C., et al. Atorvastatin correlates with decreased risk of esophageal cancer: a population-based case-control study from Taiwan. Libyan J Med 2012, 7:18830.
42. Hippisley-Cox J., Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ 2010, 340:c2197.
43. Bhutta H.Y., Alexandre L., Clark A., et al. Mo1542 do statins prevent the histological subtypes of esophageal cancer?. Prospective data from the UK General Practice Research Database (GPRD). Gastroenterology 2012, 142:S-624.
44. Nguyen D.M., El-Serag H.B., Henderson L., et al. Medication usage and the risk of neoplasia in patients with Barrett's esophagus. Clin Gastroenterol Hepatol 2009, 7:1299-1304.
45. Jung K.W., Talley N.J., Romero Y., et al. Epidemiology and natural history of intestinal metaplasia of the gastroesophageal junction and Barrett's esophagus: a population-based study. Am J Gastroenterol 2011, 106:1447-1455. quiz 1456.
46. Liao L.M., Vaughan T.L., Corley D.A., et al. Nonsteroidal anti-inflammatory drug use reduces risk of adenocarcinomas of the esophagus and esophagogastric junction in a pooled analysis. Gastroenterology 2012, 142:442-452e5. quiz e22-e23.
47. Corley D.A., Kerlikowske K., Verma R., et al. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 2003, 124:47-56.
48. Alexandre L., Clark A.B., Cheong E., et al. Systematic review: potential preventive effects of statins against oesophageal adenocarcinoma. Aliment Pharmacol Ther 2012, 36:301-311.
49. Fang D., Das K.M., Cao W., et al. Barrett's esophagus: progression to adenocarcinoma and markers. Ann N Y Acad Sci 2011, 1232:210-229.
50. Hawk E.T., Viner J.L. Statins in esophageal cancer cell lines: promising lead?. Am J Gastroenterol 2008, 103:838-841.
51. Patrick A.R., Shrank W.H., Glynn R.J., et al. The association between statin use and outcomes potentially attributable to an unhealthy lifestyle in older adults. Value Health 2011, 14:513-520.
52. Marcelli M., Cunningham G.R., Haidacher S.J., et al. Caspase-7 is activated during lovastatin-induced apoptosis of the prostate cancer cell line LNCaP. Cancer Res 1998, 58:76-83.
53. Wu J., Wong W.W., Khosravi F., et al. Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis. Cancer Res 2004, 64:6461-6468.
54. Rao S., Porter D.C., Chen X., et al. Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc Natl Acad Sci U S A 1999, 96:7797-7802.